Table 1 Clinical variables of 853 patients between EPHA5 mutant and wild-type ones
Variables | EPHA5 mutation (%) | None (%) | P |
|---|---|---|---|
Total | 65 (100) | 788 (100) | Ā |
Age | Ā | Ā | 0.544 |
Ā Ā <ā65 | 38 (58.5) | 430 (54.6) | Ā |
Ā Ā ā„ā65 | 27 (41.5) | 358 (45.4) | Ā |
Race | Ā | Ā | 0.521 |
Ā Ā White | 43 (66.2) | 573 (72.7) | Ā |
Ā Ā Asian | 15 (23.1) | 149 (18.9) | Ā |
Ā Ā Others | 7 (10.8) | 66 (8.4) | Ā |
Sex | Ā | Ā | 0.121 |
Ā Ā Female | 19 (29.2) | 307 (39.0) | Ā |
Ā Ā Male | 46 (70.8) | 481 (61.0) | Ā |
Histology | Ā | Ā | 0.493 |
Ā Ā Squamous | 17 (26.2) | 238 (30.2) | Ā |
Ā Ā Non-squamous | 48 (73.8) | 550 (69.8) | Ā |
ECOG | Ā | Ā | 0.319 |
Ā Ā 0 | 18 (27.7) | 266 (33.8) | Ā |
Ā Ā 1 | 47 (72.3) | 522 (66.2) | Ā |
Previous therapy | Ā | Ā | 0.346 |
Ā Ā First-line chemotherapy | 51 (78.5) | 576 (73.1) | Ā |
Ā Ā Second-line chemotherapy | 14 (21.5) | 212 (26.9) | Ā |
Smoking | Ā | Ā | 0.227 |
Ā Ā Current | 13 (20.0) | 125 (15.9) | Ā |
Ā Ā Never | 6 (9.2) | 134 (17.0) | Ā |
Ā Ā Previous | 46 (70.8) | 529 (67.1) | Ā |
Ā Ā Metastasis sites | Ā | Ā | 0.004 |
Ā Ā ā¤ā3 | 34 (52.3) | 547 (69.4) | Ā |
Ā Ā >ā3 | 31 (47.7) | 241 (30.6) | Ā |
Therapy | Ā | Ā | 0.859 |
Ā Ā Atezolizumab | 32 (49.2) | 397 (50.4) | Ā |
Ā Ā Docetaxel | 33 (50.8) | 9.6) | Ā |